Search the Newsreel

Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer

Celcuity Inc. announced that its newly FDA-approved drug, REVTORPYK (gedatolisib), has been included as a preferred Category 1 regimen in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines. This inclusion is for the second-line treatment of HR+/HER2- locally advanced or metastatic breast cancer …

Renaissance Technologies LLC Raises Stake in Melco Resorts & Entertainment Limited $MLCO

Renaissance Technologies LLC increased its stake in Melco Resorts & Entertainment Limited (MLCO) by 7.9% in the first quarter, now owning 1.10% of the company's stock valued at $25.34 million. Other institutional investors also adjusted their holdings, with several firms raising their stakes. Analyst …

Delcath Systems (DCTH) Projected to Post Quarterly Earnings on Thursday

Steelcast completes Q1FY27 earnings call, audio recording available online

Nelcast uploads Q1FY27 analyst call transcript after profit slump

Fuelcell Energy Inc (FCEL) Financial Health: Profitability & Balance Sheet Analysis

Fuelcell Energy Inc's (FCEL) financial score is 7.12, ranking 17th out of 28 in the Renewable Energy industry, indicating stable financial status and average operating efficiency. The company's latest quarterly revenue decreased by 4.86% year-over-year to $35.59 million, while its net profit saw a …

FuelCell Energy Inc. stock falls Wednesday, underperforms market

FuelCell Energy Inc. (FCEL) shares dropped 8.04% to $18.08 on Wednesday, underperforming the broader market. Both the NASDAQ Composite Index and the Dow Jones Industrial Average experienced significant declines. This marks the second consecutive day of losses for FuelCell Energy Inc. stock.

Celcuity's stock drops 17% after delayed launch of FDA-approved breast cancer drug Revtorpyk.

Celcuity's stock fell 17% after the company announced a delay in the commercial launch of its FDA-approved breast cancer drug, Revtorpyk, now expected in late Q3 2026. This delay has prompted a law firm, Kessler Topaz Meltzer & Check LLP, to investigate potential securities …

Celcuity Inc (CELC) Institutional Confidence

The article analyzes Celcuity Inc's (CELC) institutional confidence, noting its high score of 10.00, which ranks it 1st out of 385 in the Biotechnology & Medical Research industry. Institutional shareholding is 97.67%, with a 12.26% quarter-over-quarter increase. Steven Cohen is the largest institutional shareholder.

Melco Resorts & Entertainment Ltd (MLCO) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Melco Resorts & Entertainment Ltd (MLCO), focusing on support, resistance, indicators, and moving averages. As of July 28, 2026, MLCO's price momentum score is 3.26, and it is trading between a resistance level of $5.85 and a …

NASDAQ: CELC Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm

Kessler Topaz Meltzer & Check, LLP (KTMC) is investigating potential federal securities law violations by Celcuity Inc. (NASDAQ: CELC) after the company announced an unexpected delay in the commercial launch of its breast cancer therapy, Revtorpyk. This delayed timeline, relative to analyst expectations, caused …

Melco Resorts & Entertainment Ltd. Sponsored ADR Revenue Breakdown – LSE:0A2P

Melco Resorts & Entertainment Ltd. (LSE:0A2P) generated $5.16 billion USD in revenue last year. The City of Dreams segment was the top performer, contributing $2.74 billion USD, while Macau was the primary geographical contributor, accounting for $4.43 billion USD. This information provides a breakdown …

Pomerantz investigates Celcuity over delayed cancer drug launch and stock drop

Pomerantz LLP is investigating Celcuity Inc. and its officers for potential securities fraud. This follows Celcuity's announcement of a delayed launch for its FDA-approved breast cancer drug, Revtorpyk, which caused a 17.6% drop in its stock price. The investigation will examine whether unlawful business …

Delcath Systems Inc (DCTH) Institutional Confidence

The article analyzes Delcath Systems Inc's (DCTH) institutional confidence, noting its current score of 3.00, placing it 130th out of 199 in the Healthcare Equipment & Supplies industry. Institutional shareholding decreased by 20.44% quarter-over-quarter, with Bill Nygren | OAKMX being the largest institutional shareholder …

BlackRock, Inc. (NASDAQ: FCEL holder) discloses 6.2% FuelCell Energy stake

BlackRock, Inc. has disclosed a 6.2% beneficial ownership stake in FuelCell Energy, Inc. (NASDAQ: FCEL), according to a Schedule 13G SEC filing. This amounts to 4,165,779 shares, with BlackRock holding sole voting power over 4,106,535 shares and sole dispositive power over all 4,165,779 shares. …

Does FuelCell Energy’s (FCEL) New On-Site PPAs Reveal a Shift in Its Competitive Strategy?

FuelCell Energy recently introduced new high-temperature on-site fuel cell systems for manufacturers, coupled with Power Purchase Agreement (PPA) financing, aiming to broaden access to lower-emission power and improve energy reliability. While these developments could boost order flow and facilitate larger installations through their Siemens …

Liver-cancer treatment company Delcath heads to Boston Aug. 11

Delcath Systems, an interventional oncology company specializing in liver cancer treatments, announced that its management will attend the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11, 2026. The company focuses on its proprietary products, HEPZATO KIT and CHEMOSAT, which deliver high-dose …

Bloom Energy Sinks 13%, FuelCell Drops 7%, Plug Power Falls 4% Ahead of Bloom’s Q2 Report

Quick Read Bloom Energy (BE) sank 13% ahead of Q2 earnings after Hunterbrook Capital alleged hidden Chinese supplier reliance, dragging FuelCell Energy (FCEL) down 7%. Bloom Energy's 15% weighting in the HYDR hydrogen ETF sent the fund down 7%, exposing the concentration risk investors …

Mediwelcome Signals Profit Rebound on Surging AI-Driven Revenue

Nelcast Q1 Results FY27: PAT Rs 5 Cr, Revenue Rs 341 Cr

Mediwelcome Healthcare Management & Technology Inc. Provides Earnings Guidance for the Six Months Ended 30 June 2026

Nelcast Q1 Results: Net profit drops 59% YoY to ₹5.14 crore

Celcuity Inc. (CELC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Celcuity Inc. (NASDAQ:CELC) shareholders after the company announced a delayed commercial launch for its breast cancer therapy Revtorpyk. This delay, relative to analyst expectations, caused Celcuity's stock price to fall by 17.6% …

How FuelCell Energy Supports Smarter Manufacturing Operations

FuelCell Energy FCEL is strengthening its relevance in the manufacturing industry by offering on-site fuel cell systems that blend continuous power generation with combined heat and power ("CHP") capabilities. The clean energy company is targeting manufacturers seeking greater energy reliability, lower emissions and improved …

Delcath Systems Inc (DCTH) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Delcath Systems Inc (DCTH) stock performance and dividend history. It indicates that the company has not distributed any dividends over the past five years. The page also presents current stock pricing, market capitalization, and P/E ratio for DCTH.

Nelcast shares crash 14% after Q1 profit slumps 59% YoY to Rs 5.13 crore, EBITDA margins weaken

Nelcast Q1FY27 net profit falls 59% to ₹5.14 crore on cost pressures

Nelcast consolidated net profit declines 58.88% in the June 2026 quarter

DCTH|Delcath Systems Inc|Price:11.960|Chg%:-0.260

This article provides a comprehensive stock analysis of Delcath Systems Inc (DCTH) from TradingKey, highlighting its healthy fundamentals, high growth potential, and "Buy" ratings from analysts with a target price of $22.33. Despite recent weak market performance, the company shows strong fundamentals and is …

Fuelcell Energy Inc (FCEL) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on Fuelcell Energy Inc's (FCEL) dividend and stock split history. It indicates that FCEL has not distributed any dividends over the past five years. However, it lists several "Merger" type stock splits with a 30:1 ratio scheduled for November 07, …

FCEL|Fuelcell Energy Inc|Price:21.260|Chg%:-2.040

Fuelcell Energy Inc (FCEL) closed at $21.260, experiencing an 8.76% drop. Despite a recent weak stock market performance, the company shows significant growth potential and healthy fundamentals, with analysts largely rating it as 'Hold' and a target price of $22.83. The stock is currently …

Celcuity Inc. Revenue Breakdown – NASDAQ:CELC

This article provides financial information for Celcuity Inc. (NASDAQ: CELC) on TradingView. It offers an overview of the company's financials, including statements, statistics, dividends, earnings, and segment performance. The content is primarily a navigation hub within the TradingView platform, detailing available data and tools …

MLCO|Melco Resorts & Entertainment Ltd|Price:5.410|Chg%:-0.160

Melco Resorts & Entertainment Ltd (MLCO) is trading at $5.41, down 2.87% for the day. Analysts rate the stock as a "Buy" with a target price of $8.30, representing a 49.01% upside. The company, which operates casinos and resort facilities in Macau and the …

Fuelcell Energy Inc (FCEL) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Fuelcell Energy Inc (FCEL), detailing its current earnings forecast score, average price target, and analyst ratings. It highlights that FCEL ranks 16 out of 28 in the Renewable Energy industry with an average price target of $7.53, …

FuelCell Energy, Inc. Revenue Breakdown – EUROTLX:4FEY2

FuelCell Energy, Inc. (EUROTLX:4FEY2) reported a total revenue of ‪137.09 M‬ EUR last year. The Product segment was the highest contributor, generating ‪59.92 M‬ EUR, a significant increase from the previous year's ‪23.59 M‬ EUR. The United States was the primary regional contributor, accounting …

Celcuity's Gedatolisib: Regulatory Win Meets Commercial Reality

Celcuity (CELC) has received FDA approval for its breast cancer drug, gedatolisib, marking a significant regulatory milestone. However, the article emphasizes that regulatory success is only the beginning, and commercial success is far from guaranteed due to intense market competition, payer scrutiny, and the …